Equillium Stock Today

EQ Stock  USD 0.92  0.02  2.22%   

Performance

2 of 100

 
Weak
 
Strong
Weak

Odds Of Distress

Less than 9

 
High
 
Low
Low
Equillium is selling at 0.92 as of the 13th of October 2024; that is 2.22 percent increase since the beginning of the trading day. The stock's last reported lowest price was 0.88. Equillium has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for Equillium are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of September 2024 and ending today, the 13th of October 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
11th of October 2018
Category
Healthcare
Classification
Health Care
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. The company has 35.42 M outstanding shares of which 190.49 K shares are currently sold short in the market by investors with about 1.81 days to cover all shorted shares. More on Equillium

Moving against Equillium Stock

  0.53DRMA Dermata TherapeuticsPairCorr

Equillium Stock Highlights

Chairman of the Board, CEODaniel Bradbury
Thematic IdeaPharmaceutical Products (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.370.7141
Way Down
Slightly volatile
Gross Profit Margin0.790.9965
Significantly Down
Slightly volatile
Total Current Liabilities29 M27.6 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total364.8 K384 K
Notably Down
Slightly volatile
Total Assets67.5 M50.5 M
Significantly Up
Slightly volatile
Total Current Assets66.9 M49.3 M
Significantly Up
Slightly volatile
Debt Levels
Equillium can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Equillium's financial leverage. It provides some insight into what part of Equillium's total assets is financed by creditors.
Liquidity
Equillium reports 824 K of total liabilities with total debt to equity ratio (D/E) of 0.29, which may suggest the company is not taking enough advantage from financial leverage. Equillium has a current ratio of 3.9, indicating that it is in good position to pay out its debt commitments in time. Note however, debt could still be an excellent tool for Equillium to invest in growth at high rates of return.

Capital Expenditures

47,500
Equillium (EQ) is traded on NASDAQ Exchange in USA. It is located in 2223 Avenida De La Playa, La Jolla, CA, United States, 92037 and employs 45 people. Equillium is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a market capitalization of 32.59 M. Equillium is active under Biotechnology sector as part of Health Care industry. The entity has 35.42 M outstanding shares of which 190.49 K shares are currently sold short in the market by investors with about 1.81 days to cover all shorted shares. Equillium reports about 57.56 M in cash with (21.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Equillium Probability Of Bankruptcy
Ownership Allocation
Equillium holds a total of 35.42 Million outstanding shares. Equillium retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Equillium Ownership Details

Equillium Stock Institutional Holders

InstituionRecorded OnShares
Northern Trust Corp2024-06-30
35 K
Dcf Advisers, Llc2024-06-30
33 K
Hrt Financial Llc2024-06-30
30.5 K
Commonwealth Equity Services Inc2024-06-30
25 K
Tritonpoint Wealth Llc2024-06-30
13.5 K
Stifel Financial Corp2024-06-30
10.1 K
Simplex Trading, Llc2024-06-30
9.1 K
Ubs Group Ag2024-06-30
6.3 K
Wells Fargo & Co2024-06-30
1000
Decheng Capital Llc2024-06-30
4.4 M
Vanguard Group Inc2024-06-30
841.9 K
View Equillium Diagnostics

Equillium Historical Income Statement

At this time, Equillium's Interest Income is relatively stable compared to the past year. As of 10/13/2024, Interest Expense is likely to grow to about 748.9 K, while Net Loss is likely to drop (8.6 M). View More Fundamentals

Equillium Stock Against Markets

Equillium Corporate Management

Jason KeyesChief OfficerProfile
Matthew RitterSenior DevelopmentProfile
Penny TomPrincipal OfficerProfile
Maple MDChief OfficerProfile
Krishna MDConsultantProfile

Additional Tools for Equillium Stock Analysis

When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.